J&J/Animas (JNJ) Pump Exit Positive for Medtronic (MDT), Insulet (PODD), and Tandem Diabetes (TNDM) - Cowen

October 5, 2017 12:49 PM EDT
Get Alerts MDT Hot Sheet
Price: $123.23 -1.58%

Rating Summary:
    26 Buy, 12 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 15 | Down: 13 | New: 24
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Cowen analyst Doug Schenkel said J&J/Animas (NYSE: JNJ) exit from the pump business is a positive for Medtronic (NYSE: MDT), Insulet (NASDAQ: PODD), and Tandem Diabetes (NASDAQ: TNDM).

Schenkel notes close to 10% of the US insulin pump market is now up for grabs over the next 2 years.

The analyst said appears likely to get the majority of patients initially, but this is also a great opportunity for PODD/TNDM.

Meanwhile, he said there is a risk for DexCom (NASDAQ: DXCM), though they believe the vast majority of DXCM users will remain DXCM users, regardless of pump choice.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Cowen & Co